A few recent studies are exploring the use of pulsed frequency fields (think Rife and PEMF) to aide the cell’s absorption/uptake of chemotherapy drugs. The beneficial effects of chemotherapeutic drugs are impeded by their poor permeation through the cell membrane, and, if they can’t get into the cell, they can’t kill it. According to some recent studies, this limitation can be overcome by a novel approach called electroporation therapy (EPT), electrochemotherapy (ECT), or electrical impulse chemotherapy (EIC) – the “new names” for some decades-old therapies.
They state that the method involves application of brief electrical pulses, which destabilize the cell membrane barrier, allowing intracellular access of chemotherapeutic drugs that otherwise would not be able to penetrate the cell membrane effectively. “EPT makes it possible to lower the drug dose, thereby relieving the patient of adverse side effects associated with conventional chemotherapy. Even with the lower drug dose, EPT has shown significantly higher efficacy than has conventional chemotherapy.” 
I really should be excited. Research is ‘discovering’ that what I and others have shouted (to deaf ears) for a long time. I should be excited but I must admit, I’m a little perturbed, maybe just tired. Rife and PEMF are not magic wands, I’ve always stated that, but they can increase th effectiveness of any therapy the patient may choose, whether nutritional or conventional.
The research is ongoing and is currently being evaluated clinically for treating various cancer indications using the anticancer drugs bleomycin or cisplatin. This article provides a historical perspective and current insights into this new modality of cancer treatment, including basic physical, biological, and medical facts about EPT; computer-assisted development of electrical pulse generators and electrodes necessary to create effective electrical fields in the treatment area; results of cancer cell and tumor treatments in vitro, in animals, and in humans; safety aspects of EPT; potential combined delivery of chemotherapeutic drugs and biological agents to reduce or eliminate metastatic disease; and intracellular delivery of DNA by electroporation for cancer gene therapy.
 Critical Reviews™ in Therapeutic Drug Carrier Systems DOI: 10.1615/CritRevTherDrugCarrierSyst.v16.i6.10